Physician profile
Kelly Sutherland
NPI 1205331600
$1,229.25
in general payments reported to CMS, 2019-2025
18 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $162 · 2024: $562 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $235.85 | 2023-2025 | Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $171.23 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $131.28 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $126.27 | 2023-2024 | Jornay Pm |
| Abbvie INC. | $99.97 | 2024-2025 | |
| Corium, LLC | $91.31 | 2024-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $82.41 | 2024-2025 | Fanapt |
| Lundbeck LLC | $58.10 | 2024 | Rexulti |
| Boston Scientific Corporation | $42.14 | 2023 | Lithovue |
| Sage Therapeutics, LLC | $30.58 | 2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $28.48 | 2024 | Trintellix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.47 | 2025 | Rejoyn |
| Collegium Pharmaceutical, INC. | $20.94 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $20.42 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $19.47 | 2025 | Austedo Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $17.39 | 2025 | The Cologuard Plus Collection Kit |
| Vertical Pharmaceuticals, LLC | $14.45 | 2024 | Relexxii |
| Neos Therapeutics, LP | $13.49 | 2025 | Cotempla Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.